Introduction {#s1}
============

Syphilis has been resurgent in many parts of the world in past decades [@pntd.0001273-Fenton1]--[@pntd.0001273-Tucker1]. This important sexually transmitted infection can facilitate the transmission of HIV infection [@pntd.0001273-Buchacz1], [@pntd.0001273-Zetola1], increase the risk of adverse pregnancy outcomes [@pntd.0001273-Doroshenko1], and cause substantial economic impact [@pntd.0001273-Pultorak1], [@pntd.0001273-Schmid1]. Understanding the epidemiology of syphilis is important for estimating disease burdens, monitoring epidemic trends, and evaluating intervention activities.

Molecular typing is a powerful tool for determining diversity and epidemiology of infections, especially for *Treponema pallidum* (*T. pallidum*), an organism that cannot be cultured *in vitro* [@pntd.0001273-Lafond1]. In addition, molecular typing has the potential to enhance clinical care, prevention, and control efforts by contributing to a better understanding of *T. pallidum* acquisition and transmission [@pntd.0001273-Morshed1]. The first molecular typing method was introduced by the United States Centers for Disease Control and Prevention (U.S. CDC) and is based on the interstrain variability of acidic repeat protein gene (*arp*) and *T. pallidum* repeat gene subfamily II (*tprE*, *G* and *J*, hereinafter referred to as *tpr*) [@pntd.0001273-Pillay1]. The typing result is named subtype [@pntd.0001273-Pillay1]. Besides the above two genes, a recent study in San Francisco introduced a third gene named *rpsA* that could be targeted to improve the discriminatory ability of the typing system or to further delineate the common strain type [@pntd.0001273-Katz1]. Moreover, another recent study developed a third gene named *tp0548* with a better discriminatory typing power, and the typing result is named strain type [@pntd.0001273-Marra1].

Previous studies of *T. pallidum* molecular typing have used multiple specimens from patients with different stages of syphilis. It has been reported that specimens from moist skin lesions have a higher yield of typeable DNA [@pntd.0001273-Florindo1], [@pntd.0001273-Castro1], that the lower efficiency of *arp* gene PCR assay may be related to poor full typing efficiency [@pntd.0001273-Florindo1], [@pntd.0001273-Pillay2], and that specific *T. pallidum* subtypes are likely associated with macrolide resistance or neurosyphilis [@pntd.0001273-Katz1], [@pntd.0001273-Marra1], [@pntd.0001273-Martin1]--[@pntd.0001273-Molepo1]. This study aimed to systematically review and investigate the published research on molecular typing of *T. pallidum* in order to: (1) determine more suitable specimen types for the molecular epidemiological study of syphilis; (2) determine *T. pallidum* subtype distribution across geographic areas; and (3) summarize available information on subtypes associated with neurosyphilis and macrolide resistance.

Methods {#s2}
=======

Literature search {#s2a}
-----------------

Two independent researchers (RRP and JL) searched five databases (PubMed, Embase, EBSCO, Google Scholar, and CNKI) to identify published studies from 1998, when the first typing method was introduced, through 2010. Search terms included "*Treponema pallidum*," or "syphilis," combined with the subject headings "molecular," "subtyping," "typing," "genotype," and "epidemiology." References cited in the retrieved articles were evaluated for inclusion, but duplicate reports were excluded. The search was conducted in four stages (identification, screening, eligibility, and inclusion) according to PRISMA guidelines [@pntd.0001273-Moher1], [@pntd.0001273-Liberati1].

Eligibility criteria and validity assessment {#s2b}
--------------------------------------------

The inclusion criteria consisted of the following items: (1) original studies published from 1998 through 2010 in any language; (2) description of the source of clinical specimens; (3) utilization of the *arp* and *tpr* genes, or an additional third gene for molecular typing; (4) description of typing methods; and (5) report of absolute number of each subtype category. Two researchers (RRP and JL) assessed the eligibility and validity of the studies independently according to the criteria. Any disagreement was resolved by involving of the third researcher (ALW).

Data extraction {#s2c}
---------------

We extracted the following data from each study using a standardized form ([Table 1](#pntd-0001273-t001){ref-type="table"}): (1) first author and publication year; (2) country and location where the study was conducted; (3) study population; (4) specimen collection period; (5) clinical stage of syphilis; (6) specimen type (primary ulcer, secondary lesion, whole blood, plasma, blood collected from scraping the ear lobe \[hereinafter referred to as ear lobe scraping\], and cerebrospinal fluid \[CSF\]); (7) gene for confirming *T. pallidum* DNA in PCR assay (*tpp47*, *bmp* or *polA*); (8) number of specimens collected, and number of each type of specimen collected, if available; (9) number of specimens with positive *T. pallidum* DNA, and number of each type of specimen with positive *T. pallidum* DNA, if available; (10) number of specimens with positive amplification of *arp* or *tpr*; (11) number of fully-typed specimens, and number of each type of fully-typed specimen, if available (fully-typed specimen is specimen that can be fully typed by two genes--*arp* and *tpr* or by three genes--*arp*, *tpr*, *and rpsA* or *tp0548*); (12) number of each subtype identified; (13) macrolide resistance data, if available; and (14) subtype associated with neurosyphilis, if available.

10.1371/journal.pntd.0001273.t001

###### Overview of 16 studies on molecular typing of *T. pallidum* clinical strains.

![](pntd.0001273.t001){#pntd-0001273-t001-1}

  First author, publication year                                                                Country, location, study population[a](#nt101){ref-type="table-fn"}                                         Specimen collection period                      Clinical stage of syphilis[b](#nt102){ref-type="table-fn"}                                                          Specimen type[c](#nt103){ref-type="table-fn"}                                                           Gene for *T. pallidum* detection[d](#nt104){ref-type="table-fn"}   No. of specimens   No. of subtypes identified                                       
  ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------ ---------------------------- ----- ----- ------------------------ ------------------
  Pillay A, 1998 [@pntd.0001273-Pillay1] [f](#nt106){ref-type="table-fn"}        U.S., 10 cities, GUD patients; Madagascar, primary syphilis; South Africa, 3 cities, GUD patients                                     N/A                                                              P                                                                                                             PU                                                                                                            *tpp47*                                      N/A                      55               55    38              38                 7; 8; 3
  Sutton MY, 2001 [@pntd.0001273-Sutton1]                                                                                U.S., Arizona, SP                                                                       03/1998--10/1999                                                    P, S, L                                                                                                        PU, WB                                                                                                           *polA*                                       85                      56               N/A   N/A             45                    10
  Pope V, 2005 [@pntd.0001273-Pope1]                                                                            U.S., North and South Carolina, SP                                                               11/1999--01/2003                                                      P, S                                                                                                         PU, SL                                                                                                           *polA*                                       61                      27               N/A   N/A             23                    7
  Katz KA, 2010 [@pntd.0001273-Katz1] [g](#nt107){ref-type="table-fn"}                                                U.S., San Francisco, SP                                                                    11/2004--11/2007                                                      P, S                                                                                                         PU, SL                                                                                                           *polA*                                       74                      71               69    70              69                    8
  Marra CM, 2010 [@pntd.0001273-Marra1] [h](#nt108){ref-type="table-fn"}     U.S., Seattle, 87% MSM; Madagascar; U.S., San Francisco; U.S., Baltimore; China, Nanjing; Ireland, Dublin   1999--2008; 2003--2008; 2001--2007; 1999--2001; 2006--2007; 2002                            P, S, L                                                                                                   PU, SL, WB, CSF                                                                                                        N/A                                        N/A                     N/A               N/A   N/A   84; 20; 19; 15; 10; 10   8; 6; 4; 5; 2; 4
  Martin IE, 2010 [@pntd.0001273-Martin2]                                                                  Canada, Alberta and Northwest territories, SP                                                         02/2007--04/2009                                                    P, S, C                             PU, SL, WB, PS[i](#nt109){ref-type="table-fn"}, SS[i](#nt109){ref-type="table-fn"}, CSF[i](#nt109){ref-type="table-fn"}, VEF[i](#nt109){ref-type="table-fn"}                       *bmp, tpp47* and *polA*                              449                      43               43    36              36                    4
  Cruz AR, 2010 [@pntd.0001273-Cruz1]                                                      Colombia, Cali, from a network of public sector primary health care providers                                            2003--2009                                                          S                                                                                                           SL, WB                                                                                                           *polA*                                       38                      20                6     8              6                     4
  Zeng TB, 2004 [@pntd.0001273-Zeng1]                                                                            China, Hengyang and Jiangmen, SP                                                                02/2002--01/2004                                                       P                                                                                                             PU                                                                                                             *polA*                                       85                      69               57    63              57                    8
  Zhan LS, 2005 [@pntd.0001273-Zhan1]                                                                             China, South Hunan Province, SP                                                                02/2002--08/2004                                                       P                                                                                                             PU                                                                                                             *polA*                                       52                      43               43    41              38                    10
  Zheng HP, 2005 [@pntd.0001273-Zheng1]                                                                                China, Guangzhou, MSP                                                                        2002--2004                                                          P                                                                                                             PU                                                                                                             *bmp*                                        62                      54               47    49              47                    7
  Martin IE, 2009 [@pntd.0001273-Martin1]                                                                          China, Shanghai, GUD patients                                                                 12/2007--05/2008                                                       P                                                                                           PU, WB[i](#nt109){ref-type="table-fn"}                                                                                  *bmp, tpp47* and *polA*                               57                      38               36    38              36                    4
  Pillay A, 2002 [@pntd.0001273-Pillay2]                                                                            South Africa, 5 cities, MSP                                                                     1996--2000                                                          P                                                                                                             PU                                                                                                       *tpp47* or *polA*                                 1954                    201               161   175            161                    35
  Molepo J, 2007 [@pntd.0001273-Molepo1]                                                                South Africa, Pretoria, patients in neurology ward                                                       06/1999--09/2000                                                       LN                                                                                                           CSF                                                                                                            *tpp47*                                       50                      28               13    15              13                    4
  Florindo C, 2008 [@pntd.0001273-Florindo1]                                                                           Portugal, Lisbon, SP                                                                         2004--2007                                                         P, S                                                                                                       PU, SL, WB                                                                                                    *bmp* and *polA*                                 N/A                      86               N/A   N/A             42                    3
  Castro R, 2009 [@pntd.0001273-Castro1]                                                                               Portugal, Lisbon, SP                                                                      06/2003--07/2005                                                    P, S, L                                                                                                 PU, SL, WB, PS, ELS                                                                                                     *polA*                                      212                      90               N/A   N/A             62                    5
  Cole MJ, 2009 [@pntd.0001273-Cole1]                                                                                   U.K., Scotland, MSM                                                                      08/2006--12/2007                                                      P, S                                                                                                       GU, AU, OU                                                                                                         *polA*                                      N/A                      75               61    64              58                    6

Study population: GUD-genital ulcer disease, SP-STD patients, including males and females, MSP-male STD patients, and MSM-men who have sex with men.

Clinical stage of syphilis: P-primary syphilis, S-secondary syphilis, L-latent syphilis, C-congenital syphilis, and LN-late neurosyphilis.

Specimen type: PU-primary ulcer, WB-whole blood, SL-secondary lesion, including secondary skin lesion and/or mucosal lesion, CSF-cerebrospinal fluid, PS-plasma specimen, SS-serum specimen, VEF-vitreous eye fluid, ELS-ear lobe scraping, GU-genital ulcer, AU-anal ulcer, and OU-oral ulcer.

Gene for *T. pallidum* detection: *tpp47*-47 kDa protein gene, *bmp*-basic membrane protein gene, and *polA*-DNA polymerase I gene.

Full type was based on two genes (*arp* and *tpr*) or three genes (*arp*, *tpr*, and *rpsA or tp0548*).

Eight laboratory strains were excluded, remaining 55 clinical strains were included for analysis.

Introducing a third gene, *rpsA*.

Introducing a third gene, *tp0548*. Laboratory strains were excluded.

*T. pallidum* DNA was not amplified successfully by screening PCR assay.

Statistical analysis {#s2d}
--------------------

DNA extraction efficiency was defined as a proportion of *T. pallidum* positive specimens out of all extracted specimens. Molecular typing efficiency was defined as a proportion of fully-typed specimens out of *T. pallidum* positive specimens. We performed a pooled analysis of subtype distribution by country location. One study identified subtypes in three countries (U.S., Madagascar, and South Africa), so the subtypes were disaggregated [@pntd.0001273-Pillay1].

We used Statistical Package for the Social Sciences for Windows (SPSS, version 18.0, Chicago, IL, USA) and Comprehensive Meta-Analysis software (CMA, version 2.0, Biostat Inc., Englewod, NJ, USA) for statistical analysis. Point estimates with corresponding 95% confidence intervals (CI) for DNA extraction efficiency and typing efficiency were carried out for each individual study if available. A chi-square test (*p*\<0.05 indicating statistical significance) was applied to compare the different categories. Q test (*p*\<0.10 indicating statistical significance) and I^2^ value (ranging between 0% and 100%, with lower value representing less heterogeneity) were calculated to measure between-study heterogeneity [@pntd.0001273-Higgins1]. A random-effects model was used to perform the subgroup analysis. Publication bias was assessed by the Begg rank correlation test (*p*\<0.05 indicating statistical significance) [@pntd.0001273-Borenstein1].

Results {#s3}
=======

Study selection {#s3a}
---------------

As shown in [Figure 1](#pntd-0001273-g001){ref-type="fig"}, 370 potential abstracts were identified, and 111 duplicate records were removed. Of the remaining abstracts, all were screened, and 226 that did not study the molecular typing of syphilis were excluded. Thirty-three full-text articles were assessed for eligibility and of those, 16 studies were included ([Table 1](#pntd-0001273-t001){ref-type="table"}) [@pntd.0001273-Pillay1]--[@pntd.0001273-Molepo1], [@pntd.0001273-Sutton1]--[@pntd.0001273-Cole1]. No additional eligible studies were identified by checking the references of retrieved articles. Fourteen studies used two genes (*arp* and *tpr*) for molecular typing [@pntd.0001273-Pillay1], [@pntd.0001273-Florindo1]--[@pntd.0001273-Molepo1], [@pntd.0001273-Sutton1]--[@pntd.0001273-Cole1], and two recent studies used three genes (*arp*, *tpr*, and *rpsA* or *tp0548*) [@pntd.0001273-Katz1], [@pntd.0001273-Marra1].

![Search strategy of published studies according to PRISMA guidelines.](pntd.0001273.g001){#pntd-0001273-g001}

DNA extraction efficiency {#s3b}
-------------------------

DNA extraction efficiency ranged from 10.3% to 95.9% based on 12 studies ([Figure 2](#pntd-0001273-g002){ref-type="fig"}) [@pntd.0001273-Katz1], [@pntd.0001273-Castro1]--[@pntd.0001273-Molepo1], [@pntd.0001273-Sutton1]--[@pntd.0001273-Zheng1]. The median was 60.9% with an inter-quartile range (IQR) of 43.0%--82.3%. Blood specimens resulted in a lower yield of *T. pallidum* DNA compared to skin specimens (30.0% *vs.* 85.7%, χ^2^ = 245.2, *p*\<0.001). No obvious publication bias was observed (Begg rank correlation test, *p* = 0.11).

![Forest plot of DNA extraction and molecular typing efficiency from 15 studies.\
Proportion represents DNA extraction efficiency or full typing efficiency. Lower limit and upper limit represent 95% confidence intervals.](pntd.0001273.g002){#pntd-0001273-g002}

Strong evidence of heterogeneity (I^2^ = 98.4%, *p*\<0.001) was observed between studies. Subgroup analysis by specimen type partly reduced the heterogeneity ([Table 2](#pntd-0001273-t002){ref-type="table"}). Primary and secondary lesions and ear lobe blood specimens had an average higher yield of *T. pallidum* DNA (83.0% *vs.* 28.2%, χ^2^ = 247.6, *p*\<0.001) compared to plasma, whole blood and CSF. DNA extraction from CSF was more efficient than from whole blood and plasma (33.6% *vs.* 24.5%, χ^2^ = 13.4, *p*\<0.001). Whole blood and plasma had the lowest DNA extraction efficiency, with no significant difference between the two (25.0% *vs.* 13.0%, χ^2^ = 1.0, *p* = 0.32).

10.1371/journal.pntd.0001273.t002

###### Subgroup analysis of DNA extraction and molecular typing efficiency by specimen type.

![](pntd.0001273.t002){#pntd-0001273-t002-2}

  Specimen type                                        Efficiency % (95% CI)   No. of studies   Heterogeneity  
  --------------------------------------------------- ----------------------- ---------------- --------------- -------
  **DNA extraction**                                                                                           
  Primary ulcer                                          86.4 (80.0--90.9)           7              48.9        0.07
  Secondary lesion                                       75.0 (57.8--86.8)           4                0         0.71
  Ear lobe scraping[a](#nt110){ref-type="table-fn"}      65.6 (47.9--79.8)           1                         
  Plasma                                                 13.0 (0.5--81.2)            2              82.8        0.02
  Whole blood                                            25.0 (13.5--41.6)           5              76.7        0.002
  Cerebrospinal fluid                                    33.6 (4.1--85.6)            2              67.5        0.08
  **Molecular typing**                                                                                         
  Primary ulcer                                          82.8 (75.3--88.3)           9              66.7        0.002
  Secondary lesion                                       71.9 (50.2--86.6)           4                0         0.57
  Ear lobe scraping[a](#nt110){ref-type="table-fn"}      76.2 (54.0--89.7)           1                         
  Plasma                                                 62.5 (44.9--77.3)           1                         
  Whole blood                                            34.5 (17.7--56.4)           4              65.0        0.04
  Cerebrospinal fluid                                    46.4 (29.2--64.6)           1                         

Blood collected from scraping the ear lobe.

When the blood specimens were disaggregated by clinical stage based on three studies, blood specimens from patients with secondary syphilis had higher yield of DNA than blood from patients with primary or latent syphilis (55.8% *vs.* 34.1% *vs.* 33.6%, χ^2^ = 7.3, *p* = 0.007) [@pntd.0001273-Castro1], [@pntd.0001273-Martin1], [@pntd.0001273-Cruz1].

Molecular typing efficiency {#s3c}
---------------------------

The difference of PCR efficiency between the *arp* and *tpr* genes was not statistically significant based on 11 studies (χ^2^ = 5.2, *p* = 0.88) [@pntd.0001273-Pillay1], [@pntd.0001273-Katz1], [@pntd.0001273-Pillay2]--[@pntd.0001273-Molepo1], [@pntd.0001273-Cruz1]--[@pntd.0001273-Cole1]. Typing efficiency ranged from 30.0% to 97.2% among 15 studies ([Figure 2](#pntd-0001273-g002){ref-type="fig"}) [@pntd.0001273-Pillay1], [@pntd.0001273-Katz1], [@pntd.0001273-Florindo1]--[@pntd.0001273-Molepo1], [@pntd.0001273-Sutton1]--[@pntd.0001273-Cole1], with the median of 80.4% and IQR of 68.9%--87.0%. Publication bias was not statistically significant (Begg rank correlation test, *p* = 0.11).

Subgroup analysis by specimen type was also conducted to reduce the obvious heterogeneity between studies (I^2^ = 84.7%, *p*\<0.001) ([Table 2](#pntd-0001273-t002){ref-type="table"}). Primary and secondary lesions and ear lobe blood specimens had an average higher efficiency of full molecular typing (80.9% *vs.* 43.1%, χ^2^ = 102.3, *p*\<0.001) compared to plasma, whole blood, and CSF. Plasma ranked in the middle of all blood specimens in terms of typing efficiency. The typing efficiency of whole blood was the lowest, with no significant difference compared with CSF (34.5% *vs.* 46.4%, χ^2^ = 1.3, *p* = 0.25).

One study that disaggregated specimens by clinical stage showed that molecular typing efficiency was borderline insignificance between specimens from primary, secondary, and latent syphilis (85.7% *vs.* 83.3% *vs.* 55.1%, χ^2^ = 6.2, *p* = 0.05) [@pntd.0001273-Castro1].

Subtype distribution {#s3d}
--------------------

Fifty-seven subtypes of *T. pallidum* were identified from 14 studies [@pntd.0001273-Pillay1], [@pntd.0001273-Florindo1]--[@pntd.0001273-Molepo1], [@pntd.0001273-Sutton1]--[@pntd.0001273-Cole1]. For the *arp* gene, a range of 2 to 22 tandem repeats (except 9 and 21) were found. For the *tpr* genes, patterns a to m and p were found. Additionally, for the *tp0548* gene, sequences c to g and i were found [@pntd.0001273-Marra1]. For the *rpsA* gene, a range of 8 to 10 and 12 tandem repeats were found [@pntd.0001273-Katz1]. South Africa, the U.S., and China had the most abundant variety of subtypes, and 38 subtypes were identified in 177 specimens, 19 subtypes were identified in 81 specimens, and 15 subtypes were identified in 178 specimens, respectively. The pooled analysis based on country showed that the distribution of the 27 most common subtypes had substantial geographic variation ([Figure 3](#pntd-0001273-g003){ref-type="fig"}). Overall, 14d, 14f, 14a, 13d, and 15d were most prevalent. The limited data on subtypes associated with neurosyphilis and macrolide resistance precluded completion of one study aimed to investigate the neuroinvasive and macrolide resistant subtypes.

![Distribution of the most common subtypes across eight geographic areas from 14 studies.](pntd.0001273.g003){#pntd-0001273-g003}

Discussion {#s4}
==========

The World Health Organization (WHO) recently estimated 10.6 million new cases of syphilis each year, and the emergence of macrolide resistant strains has increased the importance of molecular epidemiological investigations [@pntd.0001273-Schmid2], [@pntd.0001273-Stamm1]. Globally, molecular typing of *T. pallidum* clinical strains has helped characterize syphilis outbreaks [@pntd.0001273-Sutton1], [@pntd.0001273-Cole1], evaluate subtypes associated with neurosyphilis [@pntd.0001273-Marra1], [@pntd.0001273-Molepo1], monitor macrolide resistance [@pntd.0001273-Katz1], [@pntd.0001273-Martin1], [@pntd.0001273-Martin2], differentiate between relapse and re-infection episodes [@pntd.0001273-Marra1], and better understand the geographic, temporal, and population distributions of *T. pallidum* [@pntd.0001273-Pillay1], [@pntd.0001273-Marra1], [@pntd.0001273-Cole1]. Despite the public health and clinical benefits of molecular investigation of syphilis, limited numbers of studies in a few epidemic countries have focused on the molecular typing of *T. pallidum* since the first typing assay appeared.

Our review showed that extracting DNA from blood specimens resulted in a lower yield compared to skin lesions. This is consistent with another study that directly compared the two methods [@pntd.0001273-Martin3]. Previous studies indicated that this may be largely related to the lower *T. pallidum* load in blood than that in skin lesions [@pntd.0001273-Lafond1], [@pntd.0001273-Salazar1]. Moreover, PCR-inhibitory substances are more likely to exist in whole blood [@pntd.0001273-AlSoud1]. Our analysis showed that moist skin lesions from patients with primary or secondary syphilis were suitable for molecular investigation of syphilis. Additionally, ear lobe blood specimen could be an alternative when there are no visible skin lesions.

Previous studies reported results of partial molecular typing due to low success rate of the *arp* gene PCR assay [@pntd.0001273-Florindo1], [@pntd.0001273-Pillay2], [@pntd.0001273-Liu1]. Our analysis revealed that the efficiency of PCR assay between the *arp* and *tpr* genes was not statistically significant. The specimens that had most efficient molecular typing were the same specimens that yielded higher *T. pallidum* DNA--primary ulcer, secondary lesion, and ear lobe scraping. CSF from patients with late neurosyphilis resulted in 46.4% typing efficiency. Although the typing efficiency is not high, the typing results of CSF highlight the potential for typing neuroinvasive strains. Interestingly, ear lobe scrapings had the highest DNA yield and typing efficiency among blood specimens, with no significant difference compared with primary ulcers and secondary lesions. Because the ear lobe is rich in capillaries, poor in sensory nerves, and can be easily accessed [@pntd.0001273-Castro2], it has promising prospect for blood specimen collection. Since there has been only one study verifying the molecular typing efficiency of ear lobe blood specimens, the results should be validated using a larger sample size.

A surprising level of genetic diversity of *T. pallidum* was evident, with predominance of several subtypes worldwide. 14d was most prevalent, except in the U.S. (ranked third) and Portugal (ranked second). The abundant variety in subtype distribution across geographic areas could reflect regional sexual network patterns. However, the predominance of 14d may indicate some linked transmission, and 14d may be an original circulating subtype in many parts of the world.

The association between specific subtypes and neurosyphilis can lead to a detailed understanding of the molecular mechanisms underlying neurosyphilis, and neuroinvasive subtypes can be a laboratory marker for increased risk of neurosyphilis. Though successful typing from CSF has made this kind of research possible, data is still limited. Our systematic literature search identified only two studies on CSF typing. One identified 14a, 3e, 2i, and 17e in CSF from patients with late neurosyphilis [@pntd.0001273-Molepo1]. Another study showed that 14d/f was significantly associated with neurosyphilis when compared with other strain types (*p* = 0.02) [@pntd.0001273-Marra1]. However, the typing efficiency of CSF specimens was relatively lower than other specimen types, and the characteristics of specimens in which subtypes could not be identified were not available. Future investigations using a larger sample size and more sensitive typing method for CSF are warranted.

A single mutation conferring macrolide resistance of *T. pallidum* has been reported in the U.S. [@pntd.0001273-Katz1], [@pntd.0001273-Lukehart1]--[@pntd.0001273-Mitchell1], Dublin [@pntd.0001273-Lukehart1], Canada [@pntd.0001273-Martin2], [@pntd.0001273-Martin3], [@pntd.0001273-Morshed2], Shanghai [@pntd.0001273-Martin1], [@pntd.0001273-Zhou1], and the Czech Republic [@pntd.0001273-Woznicova1], [@pntd.0001273-Matejkova1]. However, resistance has not been found in some African countries (Madagascar, Tanzania, and Uganda) [@pntd.0001273-VanDamme1]--[@pntd.0001273-Kiddugavu1]. Previous studies showed that antibiotic selection may contribute to increased macrolide resistance [@pntd.0001273-Marra2], [@pntd.0001273-Mitchell1], and resistant mutations were present in at least 2 separate strains of *T. pallidum* using a molecular marker (51 base pair insertion) [@pntd.0001273-Marra2]. Further investigation of resistant subtypes using molecular typing can help elucidate the molecular mechanism of macrolide resistance, but data is still not abundant. Three of the included studies mentioned resistant subtypes. One study in Shanghai found 100% (38 patients) macrolide resistance, and subtype 14f was predominant [@pntd.0001273-Martin1]. Resistance rate was 19.4% (7/36) in West Canada, and all resistant subtypes were 14d [@pntd.0001273-Martin2]. In San Francisco, 67.7% (42/62) were macrolide resistance, and subtype 14d9 was predominant [@pntd.0001273-Katz1].

To our knowledge, this is the first literature review and meta-analysis of globally published papers on molecular typing of *T. pallidum*. Because the quality of included studies varied, the following limitations should be acknowledged. First, the sample size of fully-typed specimens was small in most studies (median of 44 and IQR of 36--61), resulting in limited statistical power and limited information on transmission networks. Second, although stratified analysis can partly reduce the between-study heterogeneity, modest heterogeneity still existed. This may have been due to study-specific factors, such as specimen quality and laboratory condition. Third, because genital specimens were available more easily from males than females, the enrollment of males was predominant in the included studies, which used genital ulcers for typing. Differences in subtype distribution between males and females may have not been detected. Finally, our study included only published studies and abstracted data from articles, not raw data, which may have resulted in some selection bias.

Future molecular epidemiological research of syphilis should be informative for effective syphilis prevention and control programs. Possible studies should be at least focused on: (1) identification of high-risk populations to trace transmission networks and treat high-risk infection sources; (2) verification of subtypes associated with macrolide resistance and neurosyphilis to aid diagnosis and treatment; and (3) research on the invasiveness and virulence of different *T. pallidum* subtypes in order to better understand of the pathology of syphilis.
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